Tagged with Regulatory

Algeria Reform is under way in Algeria, and professor Mohamed L’Hadj presents the main themes of hospital reform encompassing the roll out of homecare, international collaboration and better training for better outcomes.   What main objectives and priorities are you pursuing today? Our objectives are geared towards our ambition to provide…

Algeria President of the Health Commission at the Algerian Senate, Louisa Chachoua explores recent changes in Algeria’s healthcare sector, the potential of the new drug agency, and Algeria’s capacity to become a flagship health system for the region. A lot of things have changed since our last encounter, there is a…

Turkey Dr. Hakkı Gürsöz, president of the Turkish Medicines and Medical Devices Agency (TiTCK), provides insights into recent localization and pricing policies and delivers strong messages to both domestic and foreign companies operating in Turkey while underlining TiTCK’s ambitions to work hand-in-hand with the industry, the world’s most respected regulatory authorities…

Brexit The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been working on a cancer drug for decades and built up so much expertise that you are the absolute specialist in your field and now have to transfer all your knowledge…

Hong Kong Professor Justin Wu, chief operating officer of the Chinese University of Hong Kong (CUHK) Medical Center, shares his professional background and interest in gastroenterology, his insights into the research and commercialization environment in Hong Kong, and his hope for government, industry and academia to work together to propel Hong Kong…

Regulatory This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen receptor T cell (CAR-T) therapy for young people under 25 with cancer of the blood. Leading the way in innovative cancer cures with an unrivalled portfolio of over 20 approved oncology medicines, Novartis is the only company in the…

Turkey Dr. Ümit Dereli and Cengiz Aydın of the Association of Research-Based Pharmaceutical Companies (AIFD) inTurkey discuss significant recent changes in the Turkish ecosystem, including the improving recognition of the country’s regulatory agency, new pricing and localization policies, AIFD’s contribution to Turkey’s 11th Development Plan, and the ambition to make Turkey “a…

Portugal Portugal’s Minister of Health, Adalberto Campos Fernandes, details his three-tiered plan for national health in Portugal. He explains that empowering citizens, transforming the sector digitally and ensuring that the proximity of care is readily available to the entire nation are vital elements to combatting pressing problems concerning debt, an aging…

Regulation Herbal-based medicines or botanics have attracted strong attention around the world as part of a growing consumer enthusiasm for natural products, and in the face of a ‘prescription cascade’ in which severe side effects from combinations of classic medicine are becoming a health risk in themselves. However, regulatory frameworks have,…

China One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster of metropolises and “innovation super-hub” in China’s Greater Bay Area (GBA), is now starting to take shape as the country…

India Dr. Letitia Robinson, Director of the US FDA India Office, provides insights into the main goals and responsibilities of the FDA in India and documents the US FDA’s collaboration efforts with its Indian regulatory counterparts. Could you introduce to our international readers the US FDA’s Office of International Programs and…

Spain Santiago de Quiroga, president editor of leading Spanish pharmaceutical industry newspaper El Global and CEO of healthcare communications group WeCare-u, discusses the country’s health priorities, highlighting the upcoming Personalized Medicine Plan that the government will issue by the end of 2018 and predicts how regulators are going to find new…